According tomedia reports, recently the University of Tokyo Institute of Medical Research Professor Ichiro Ichiro, and others issued a statement that the main treatment of acute pancreatitis drug “Moxista” has the effect of preventing new coronavirus into human cells. In other words, these drugs are expected to inhibit the proliferation of the virus in the body, and other antiviral drugs will be used better.
Professor Junichiro Ishiguro and others issued a statement in 2016 arguing that the drug could be effective for MERS (Middle East Respiratory Syndrome) and found to be effective after studying a new coronavirus that is also a coronavirus.
He was launched in 1986 and has been sold as a major product. Mainly used to improve the acute symptoms of pancreatitis, intra-body blood vessels, prevention of blood in vitro blood clotting in patients with bleeding lesions or bleeding tendencies.
Virus infection in the human body, mainly in combination with the receptor protein (ACE2 receptor) present on the surface of the cell, the virus outer membrane and the cell membrane fusion.
In the case of coronaviruses, the virus S protein, when combined with the ACE2 receptor on the human cell membrane, is lysised by the proteolytic enzyme TMPRSS2, and the activation of the S protein indicates that the outer membrane of the virus interacts with the cell membrane. This is important for integration. He can significantly inhibit the entry of the virus at concentrations as low as 1-10nM.
Within this month, Professor Junichiro Ishikawa will also work with the National Center for International Medical Research and other institutions to apply the drug to a number of patients with new coronaviruses in the form of a drip, with results to be seen as soon as a few months.